Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction is a pentameric ligand-gated cation channel essential for converting neural signals into muscular action. Its unique structure enables rapid response upon neurotransmitter binding—making it vital for all voluntary movements—and it serves as an important pharmacological target both clinically and evolutionarily. It is composed of five subunits (2α1, β1, δ, and γ/ε) and is activated by acetylcholine, leading to sodium and potassium ion flux and subsequent muscle contraction. Dysfunction of this receptor is implicated in diseases like myasthenia gravis.
Agonist binding leads to channel opening and ion influx/efflux, causing membrane depolarization. Antagonists block the receptor, preventing acetylcholine binding and subsequent depolarization.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor (Neuromuscular Junction) (nAChR).